Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis

被引：0
|
作者：
Aronne, L. [1 ]
Harris, M. S. [2 ]
Roberts, M. S. [2 ]
Suschak, J. [2 ]
Tomah, S. [2 ]
He, L. [2 ]
Yang, J. [2 ]
Frias, J. P. [3 ]
Browne, S. K. [2 ]
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Altimmune Inc, Gaithersburg, MD USA
[3] Veloc Clin Res, Los Angeles, CA USA
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
60
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [21] Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    ter Wee, Piet M.
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETES CARE, 2016, 39 (11) : 2042 - 2050
  • [22] TREATMENT OF ANTIPSYCHOTIC-ASSOCIATED OBESITY WITH A GLP-1 RECEPTOR AGONIST: PROTOCOL FOR AN INVESTIGATOR-INITIATED PROSPECTIVE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLINDED INTERVENTION TRIAL - THE TAO STUDY
    Ishoy, Pelle Lau
    Broberg, B. V.
    Baandrup, Lone
    Fagerlund, Birgitte
    Glenthoj, Birte Yding
    Ebdrup, Bjorn H.
    Knop, F. K.
    Joergensen, N. R.
    Andersen, U. B.
    Rostrup, E.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S127 - S127
  • [23] Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial
    Dubourg, J.
    Ueki, K.
    Watada, H.
    Ogawa, W.
    Orza, R.
    Jacolin, B.
    Kasuga, M.
    Fouqueray, P.
    DIABETOLOGIA, 2017, 60 : S390 - S391
  • [24] Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial
    le Roux, Carel W.
    Steen, Oren
    Lucas, Kathryn J.
    Ekinci, Elif I.
    Startseva, Elena
    Unseld, Anna
    Hussain, Samina Ajaz
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2024,
  • [25] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    Urva, Shweta
    Coskun, Tamer
    Loh, Mei Teng
    Du, Yu
    Thomas, Melissa K.
    Gurbuz, Sirel
    Haupt, Axel
    Benson, Charles T.
    Hernandez-Illas, Martha
    D'Alessio, David A.
    Milicevic, Zvonko
    LANCET, 2022, 400 (10366): : 1869 - 1881
  • [26] Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
    Wan, Haijun
    Xu, Nuo
    Wang, Lijuan
    Liu, Yaping
    Fatahi, Somaye
    Sohouli, Mohammad Hassan
    Guimaraes, Nathalia Sernizon
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [27] A Phase 2, randomized, placebo-controlled, 24-Week study of the efficacy and safety of losmapimod in treating subjects with FSHD: ReDUX4
    Mellion, M.
    Tawil, R.
    Ronco, L.
    Rahilly, A.
    Rojas, A.
    Odueyungbo, A.
    Wagner, K.
    Statland, J.
    Wang, L.
    Genge, A.
    Gibson, S.
    Goyal, N.
    Hamel, J.
    Johnson, N.
    Lochmuller, H.
    LoRusso, S.
    Pestronk, A.
    Sacconi, S.
    Shieh, P.
    Cadavid, D.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S112 - S112
  • [28] The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial
    Juel, Caroline T. B.
    Lund, Asger
    Andersen, Maria M.
    Hansen, Carsten P.
    Storkholm, Jan H.
    Rehfeld, Jens F.
    van Hall, Gerrit
    Hartmann, Bolette
    Albrechtsen, Nicolai J. Wewer
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETOLOGIA, 2020, 63 (07) : 1285 - 1298
  • [29] The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial
    Caroline T. B. Juel
    Asger Lund
    Maria M. Andersen
    Carsten P. Hansen
    Jan H. Storkholm
    Jens F. Rehfeld
    Gerrit van Hall
    Bolette Hartmann
    Nicolai J. Wewer Albrechtsen
    Jens J. Holst
    Tina Vilsbøll
    Filip K. Knop
    Diabetologia, 2020, 63 : 1285 - 1298
  • [30] Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
    Roux, Carel W. Ie
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hussain, Samina Ajaz
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1773 - 1782
12345